<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750135</url>
  </required_header>
  <id_info>
    <org_study_id>21-2019</org_study_id>
    <nct_id>NCT04750135</nct_id>
  </id_info>
  <brief_title>Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis</brief_title>
  <official_title>Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hepatology &amp; Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hepatology &amp; Tropical Medicine Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary:&#xD;
&#xD;
      This is a randomized, controlled study evaluating metformin tablets administered daily for 8&#xD;
      weeks. The purpose of the study is to evaluate the efficacy and safety of metformin in the&#xD;
      treatment of mild to moderately active ulcerative colitis. Disease activity will be measured&#xD;
      using Mayo score for ulcerative colitis activity. Calculation of the score requires patients&#xD;
      to undergo colonoscopy at the start of the study and at week 8.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 7, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between the two groups in the expression of colonic (NF)-κB proteins.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will receive placebo for 8 consecutive weeks in addition to the standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will receive 500 mg Metformin TID for 8 consecutive weeks in addition to the standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin 500 mg TID Oral Tablet</intervention_name>
    <description>biguanides derivatives</description>
    <arm_group_label>Metformin group</arm_group_label>
    <other_name>Glucophage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with mild or moderate ulcerative colitis newly diagnosed by colonoscopy and&#xD;
             biopsy according to Mayo endoscopic scoring of ulcerative colitis.&#xD;
&#xD;
          2. Adults (males and/or females) with age range from 18 to 65 years old.&#xD;
&#xD;
          3. Patients on treatment with 5-aminosalisylic acid (5-ASA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe ulcerative colitis according to Mayo endoscopic scoring of&#xD;
             ulcerative colitis.&#xD;
&#xD;
          2. Treatment with systemic or rectal steroids.&#xD;
&#xD;
          3. Treatment with immunosuppressants.&#xD;
&#xD;
          4. Previously failed treatment with a sulphasalazine.&#xD;
&#xD;
          5. Known hypersensitivity to any of study drugs.&#xD;
&#xD;
          6. Hepatic and renal dysfunction.&#xD;
&#xD;
          7. Pregnancy and lactation.&#xD;
&#xD;
          8. History of colorectal carcinoma.&#xD;
&#xD;
          9. History of complete or partial colectomy.&#xD;
&#xD;
         10. Current or previous treatment with metformin for females with polycystic ovarian&#xD;
             syndrome.&#xD;
&#xD;
         11. Patients with diabetes mellitus&#xD;
&#xD;
         12. Patients with history of lactic acidosis&#xD;
&#xD;
         13. Patients with disease states associated with hypoxemia including cardiorespiratory&#xD;
             insufficiency&#xD;
&#xD;
         14. Positive stool culture for enteric pathogens, positive stool ova and parasite exam.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noha Mansour, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doaa Hamed, PhD</last_name>
    <phone>+202 23642494</phone>
    <email>Abdelaziz.h.doaa@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <state>الغربية</state>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Nahla Khalaf, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fatma elgebaly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatma Khairy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nahla Khalaf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol. 2010 Sep 7;16(33):4145-51.</citation>
    <PMID>20806430</PMID>
  </reference>
  <reference>
    <citation>Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar;134(3):688-95. doi: 10.1053/j.gastro.2007.12.012. Epub 2007 Dec 7.</citation>
    <PMID>18325386</PMID>
  </reference>
  <reference>
    <citation>Samman FS, Elaidy SM, Essawy SS, Hassan MS. New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats. Pharmacol Rep. 2018 Jun;70(3):488-496. doi: 10.1016/j.pharep.2017.11.015. Epub 2017 Nov 24.</citation>
    <PMID>29653414</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Hepatology &amp; Tropical Medicine Research Institute</investigator_affiliation>
    <investigator_full_name>Doaa abdelaziz</investigator_full_name>
    <investigator_title>Lecturer at pharmacy practice department, FUE, Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

